Sadoff JC - Search Results

1

A noncovalent complex vaccine prepared with detoxified Escherichia coli J5 (Rc chemotype) lipopolysaccharide and Neisseria meningitidis Group B outer membrane protein produces protective antibodies against gram-negative bacteremia.

Bhattacharjee AK, Opal SM, Taylor R, Naso R, Semenuk M, Zollinger WD, Moran EE, Young L, Hammack C, Sadoff JC, Cross AS. Bhattacharjee AK, et al. Among authors: sadoff jc. J Infect Dis. 1996 May;173(5):1157-63. doi: 10.1093/infdis/173.5.1157. J Infect Dis. 1996. PMID: 8627067

2

Functional activities of monoclonal antibodies to the O side chain of Escherichia coli lipopolysaccharides in vitro and in vivo.

Kim KS, Kang JH, Cross AS, Kaufman B, Zollinger W, Sadoff J. Kim KS, et al. J Infect Dis. 1988 Jan;157(1):47-53. doi: 10.1093/infdis/157.1.47. J Infect Dis. 1988. PMID: 2447199

3

The human antibody response during natural bacteremic infection with gram-negative bacilli against lipopolysaccharide core determinants.

Cross AS, Sidberry H, Sadoff JC. Cross AS, et al. Among authors: sadoff jc. J Infect Dis. 1989 Aug;160(2):225-36. doi: 10.1093/infdis/160.2.225. J Infect Dis. 1989. PMID: 2474616

4

Oral ciprofloxacin and a monoclonal antibody to lipopolysaccharide protect leukopenic rats from lethal infection with Pseudomonas aeruginosa.

Collins HH, Cross AS, Dobek A, Opal SM, McClain JB, Sadoff JC. Collins HH, et al. Among authors: sadoff jc. J Infect Dis. 1989 Jun;159(6):1073-82. doi: 10.1093/infdis/159.6.1073. J Infect Dis. 1989. PMID: 2723454

5

Safety and immunogenicity of a polyvalent Escherichia coli vaccine in human volunteers.

Cross A, Artenstein A, Que J, Fredeking T, Furer E, Sadoff JC, Cryz SJ Jr. Cross A, et al. Among authors: sadoff jc. J Infect Dis. 1994 Oct;170(4):834-40. doi: 10.1093/infdis/170.4.834. J Infect Dis. 1994. PMID: 7523536 Clinical Trial.

6

The efficacy of combination immunotherapy in experimental Pseudomonas sepsis.

Cross AS, Opal SM, Palardy JE, Bodmer MW, Sadoff JC. Cross AS, et al. Among authors: sadoff jc. J Infect Dis. 1993 Jan;167(1):112-8. doi: 10.1093/infdis/167.1.112. J Infect Dis. 1993. PMID: 8418157

7

Prevention and therapy of experimental Escherichia coli infection with monoclonal antibody.

Kim KS, Cross AS, Zollinger W, Sadoff J. Kim KS, et al. Infect Immun. 1985 Dec;50(3):734-7. doi: 10.1128/iai.50.3.734-737.1985. Infect Immun. 1985. PMID: 3934079 Free PMC article.

8

Evaluation of immunotherapeutic approaches for the potential treatment of infections caused by K1-positive Escherichia coli.

Cross AS, Zollinger W, Mandrell R, Gemski P, Sadoff J. Cross AS, et al. J Infect Dis. 1983 Jan;147(1):68-76. doi: 10.1093/infdis/147.1.68. J Infect Dis. 1983. PMID: 6401788

9

The importance of a lipopolysaccharide-initiated, cytokine-mediated host defense mechanism in mice against extraintestinally invasive Escherichia coli.

Cross A, Asher L, Seguin M, Yuan L, Kelly N, Hammack C, Sadoff J, Gemski P Jr. Cross A, et al. J Clin Invest. 1995 Aug;96(2):676-86. doi: 10.1172/JCI118110. J Clin Invest. 1995. PMID: 7635960 Free PMC article.

10

Role of lipopolysaccharide and capsule in the serum resistance of bacteremic strains of Escherichia coli.

Cross AS, Kim KS, Wright DC, Sadoff JC, Gemski P. Cross AS, et al. Among authors: sadoff jc. J Infect Dis. 1986 Sep;154(3):497-503. doi: 10.1093/infdis/154.3.497. J Infect Dis. 1986. PMID: 3525697

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

179 results

Search Page